GILD
Gilead Sciences IncHealth Careinsider_universeEverything we've seen
- ?Nov 11, 5:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $169.74 > MA150 $140.29 (+21.0%), MA rising, 3.9% off 52w high, vol 0.56× avg
- ?Nov 5, 3:35 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
With only 10 minutes remaining until the forced close, there is extremely limited time for the downward move to extend meaningfully. A -3.81% move is substantial and likely reflects real selling pressure earlier in the session, but at this stage the question is whether sellers still have firepower or whether we are approaching end-of-day mean reversion and covering. No supporting headlines to explain or sustain the move. Macro context (elevated DFF, hawkish rate environment) is modestly negative for equities broadly but GILD as a biotech/pharma name is not a primary rate-sensitive sector. With 10 minutes left, the risk of a late-day snap-back or simply no further movement before the forced flatten is high. The position would need to drop an additional ~1.5% to reach the profit target, requiring roughly 0.4% per minute — an aggressive ask in the final 10 minutes without a clear catalyst. Continuation probability is set below 0.5 due to the extreme time constraint overriding what would otherwise be reasonable momentum evidence.
- !Nov 5, 3:35 PMsignalseverity -0.04
Agent 7 — Day Trader — day_trade_skipped
With only 10 minutes remaining until the forced close, there is extremely limited time for the downward move to extend meaningfully. A -3.81% move is substantial and likely reflects real selling pressure earlier in the session, but at this stage the question is whether sellers still have firepower or whether we are approaching end-of-day mean reversion and covering. No supporting headlines to explain or sustain the move. Macro context (elevated DFF, hawkish rate environment) is modestly negative for equities broadly but GILD as a biotech/pharma name is not a primary rate-sensitive sector. With 10 minutes left, the risk of a late-day snap-back or simply no further movement before the forced flatten is high. The position would need to drop an additional ~1.5% to reach the profit target, requiring roughly 0.4% per minute — an aggressive ask in the final 10 minutes without a clear catalyst. Continuation probability is set below 0.5 due to the extreme time constraint overriding what would otherwise be reasonable momentum evidence.
- ?Nov 5, 12:45 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 2.37% intraday with no headline catalyst visible, suggesting this is flow-driven selling rather than a news event that might quickly exhaust. The move is meaningful in size — consistent with institutional distribution or sector rotation rather than a retail overreaction. Macro context shows the Fed Funds rate printing 2.1σ above its 24-month trend, which is modestly negative for rate-sensitive growth names and biotech valuations broadly, providing a mild tailwind for continued downside. With 180 minutes remaining there is ample time for the move to extend further into the close. No reversal signal is present — no news-driven spike, no morning high fade pattern described. The absence of news does not argue for a fade; it argues for organic momentum continuation. However, the probability is kept modest (0.52) because there is no confirming volume data, the macro factor is sector-indirect rather than GILD-specific, and a 2.37% move in a large-cap biotech like GILD can attract value buyers into the close. The setup marginally favors continuation down, within the system's bounded risk parameters.
- !Nov 5, 12:45 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down 2.37% intraday with no headline catalyst visible, suggesting this is flow-driven selling rather than a news event that might quickly exhaust. The move is meaningful in size — consistent with institutional distribution or sector rotation rather than a retail overreaction. Macro context shows the Fed Funds rate printing 2.1σ above its 24-month trend, which is modestly negative for rate-sensitive growth names and biotech valuations broadly, providing a mild tailwind for continued downside. With 180 minutes remaining there is ample time for the move to extend further into the close. No reversal signal is present — no news-driven spike, no morning high fade pattern described. The absence of news does not argue for a fade; it argues for organic momentum continuation. However, the probability is kept modest (0.52) because there is no confirming volume data, the macro factor is sector-indirect rather than GILD-specific, and a 2.37% move in a large-cap biotech like GILD can attract value buyers into the close. The setup marginally favors continuation down, within the system's bounded risk parameters.
- ?Nov 5, 11:25 AMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $173.02 > MA150 $139.57 (+24.0%), MA rising, 2.0% off 52w high, vol 0.03× avg
- !Nov 5, 10:10 AMsignal
Agent 1 — Immutable — insufficient_capital
- ?Nov 3, 5:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $167.50 > MA150 $139.12 (+20.4%), MA rising, 4.6% off 52w high, vol 0.63× avg
- ?Nov 2, 5:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $170.39 > MA150 $138.93 (+22.6%), MA rising, 3.0% off 52w high, vol 1.05× avg
- ?Nov 2, 5:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $170.39 > MA150 $138.93 (+22.6%), MA rising, 3.0% off 52w high, vol 1.05× avg
- ?Nov 2, 10:41 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down ~1.59% today with no attributable headlines. The move is below the 2-5% threshold that would signal strong institutional conviction, making it harder to assess whether real size is driving this or it's noise/sector rotation. Macro context (elevated mortgage rates) is not particularly relevant to GILD as a biotech/pharma name. With ~305 minutes remaining (essentially a full afternoon session), there is ample time for continuation if momentum is real, which is a mild positive for continuation. However, a sub-2% move with no catalyst and no sector tailwind is a borderline setup. No reversal pattern is evident from the data provided, and absence of news does not disqualify. The risk/reward of the system (tight -1.5% stop vs. +3% target) favors taking the trade at this threshold. Assigning minimum continuation probability of 0.5 — this is a weak momentum signal with no reason to expect a strong fade, but equally no strong reason to expect acceleration.
- !Nov 2, 10:41 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down ~1.59% today with no attributable headlines. The move is below the 2-5% threshold that would signal strong institutional conviction, making it harder to assess whether real size is driving this or it's noise/sector rotation. Macro context (elevated mortgage rates) is not particularly relevant to GILD as a biotech/pharma name. With ~305 minutes remaining (essentially a full afternoon session), there is ample time for continuation if momentum is real, which is a mild positive for continuation. However, a sub-2% move with no catalyst and no sector tailwind is a borderline setup. No reversal pattern is evident from the data provided, and absence of news does not disqualify. The risk/reward of the system (tight -1.5% stop vs. +3% target) favors taking the trade at this threshold. Assigning minimum continuation probability of 0.5 — this is a weak momentum signal with no reason to expect a strong fade, but equally no strong reason to expect acceleration.
- ?Oct 30, 10:06 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up 3.47% intraday with no attributable headline, suggesting institutional flow or possibly earnings/pipeline-related positioning. The move is meaningful in magnitude and represents real conviction. However, several factors temper enthusiasm: (1) No news catalyst identified, so the move could be fading as the session matures without fresh buyers; (2) 340 minutes remaining is actually a full trading session still ahead (market opens ~9:30 AM ET, so this reading appears early-session), giving ample time but also ample time for mean reversion; (3) The macro context (elevated mortgage rates at 2.3σ above trend) is not directly relevant to GILD as a biotech/pharma name — no sector headwind here; (4) A 3.47% gap-up or early surge without news in biotech sometimes sees late-session profit-taking as traders lock in gains ahead of close. Balancing the strong momentum signal against the absence of a catalyst and the risk of fade, a modest continuation probability above 0.5 is warranted — the system's bounded risk (-1.5% stop, +3% target) makes this a marginal but actionable long.
- !Oct 30, 10:06 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
GILD is up 3.47% intraday with no attributable headline, suggesting institutional flow or possibly earnings/pipeline-related positioning. The move is meaningful in magnitude and represents real conviction. However, several factors temper enthusiasm: (1) No news catalyst identified, so the move could be fading as the session matures without fresh buyers; (2) 340 minutes remaining is actually a full trading session still ahead (market opens ~9:30 AM ET, so this reading appears early-session), giving ample time but also ample time for mean reversion; (3) The macro context (elevated mortgage rates at 2.3σ above trend) is not directly relevant to GILD as a biotech/pharma name — no sector headwind here; (4) A 3.47% gap-up or early surge without news in biotech sometimes sees late-session profit-taking as traders lock in gains ahead of close. Balancing the strong momentum signal against the absence of a catalyst and the risk of fade, a modest continuation probability above 0.5 is warranted — the system's bounded risk (-1.5% stop, +3% target) makes this a marginal but actionable long.
- ?Oct 29, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $165.61 > MA150 $138.46 (+19.6%), MA rising, 0.1% off 52w high, vol 1.45× avg
- ?Oct 29, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $165.61 > MA150 $138.46 (+19.6%), MA rising, 0.1% off 52w high, vol 1.45× avg
- ?Oct 29, 10:36 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up 1.80% today with no headline catalyst identified, suggesting this is flow-driven rather than news-driven momentum. The move is meaningful but sits below the 2% threshold where conviction becomes more pronounced. With 310 minutes remaining (effectively the full afternoon session), there is ample time for the move to extend, which is a modest positive. The macro context (T10Y2Y at 0.29, 1.7σ below trend) reflects a flattish-to-slightly-inverted curve environment that historically supports defensives — GILD as a large-cap biotech/defensive healthcare name could benefit modestly from this backdrop as capital rotates toward defensives in a bear-flattening environment. No reversal pattern or fade signal is evident from the data provided. However, the absence of a news catalyst and the moderate magnitude of the move (not a strong momentum signal) prevent a higher probability assignment. Taking a mild continuation stance with probability just above the action threshold.
- !Oct 29, 10:36 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is up 1.80% today with no headline catalyst identified, suggesting this is flow-driven rather than news-driven momentum. The move is meaningful but sits below the 2% threshold where conviction becomes more pronounced. With 310 minutes remaining (effectively the full afternoon session), there is ample time for the move to extend, which is a modest positive. The macro context (T10Y2Y at 0.29, 1.7σ below trend) reflects a flattish-to-slightly-inverted curve environment that historically supports defensives — GILD as a large-cap biotech/defensive healthcare name could benefit modestly from this backdrop as capital rotates toward defensives in a bear-flattening environment. No reversal pattern or fade signal is evident from the data provided. However, the absence of a news catalyst and the moderate magnitude of the move (not a strong momentum signal) prevent a higher probability assignment. Taking a mild continuation stance with probability just above the action threshold.
- ?Oct 27, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $159.08 > MA150 $138.13 (+15.2%), MA rising, 0.9% off 52w high, vol 0.85× avg
- ?Oct 27, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $159.08 > MA150 $138.13 (+15.2%), MA rising, 0.9% off 52w high, vol 0.85× avg
- ?Oct 26, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $158.69 > MA150 $137.99 (+15.0%), MA rising, 1.1% off 52w high, vol 1.05× avg
- ?Oct 26, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $158.69 > MA150 $137.99 (+15.0%), MA rising, 1.1% off 52w high, vol 1.05× avg
- ?Oct 26, 10:10 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up ~2% today with no attributable headline, suggesting real institutional flow rather than a news-driven pop. A 2% move without news often reflects accumulation or a catalyst like earnings-related positioning or sector rotation into defensives — Gilead as a large-cap biotech fits the defensive rotation theme consistent with the macro context (T10Y2Y at 0.31, 1.6σ below trend, bear-flattening environment favoring defensives). With 335 minutes remaining (essentially most of the trading day still left), there is ample time for continuation. However, without a clear catalyst or volume confirmation, and with the move already pricing in meaningful upside, the probability is moderate rather than high. No reversal signals or fade pattern is evident from the data provided. Lean continuation given the bounded risk framework and favorable macro tailwind for defensive names.
- !Oct 26, 10:10 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is up ~2% today with no attributable headline, suggesting real institutional flow rather than a news-driven pop. A 2% move without news often reflects accumulation or a catalyst like earnings-related positioning or sector rotation into defensives — Gilead as a large-cap biotech fits the defensive rotation theme consistent with the macro context (T10Y2Y at 0.31, 1.6σ below trend, bear-flattening environment favoring defensives). With 335 minutes remaining (essentially most of the trading day still left), there is ample time for continuation. However, without a clear catalyst or volume confirmation, and with the move already pricing in meaningful upside, the probability is moderate rather than high. No reversal signals or fade pattern is evident from the data provided. Lean continuation given the bounded risk framework and favorable macro tailwind for defensive names.
- ?Oct 20, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $156.51 > MA150 $137.53 (+13.8%), MA rising, 2.5% off 52w high, vol 1.03× avg
- ?Oct 20, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $156.51 > MA150 $137.53 (+13.8%), MA rising, 2.5% off 52w high, vol 1.03× avg
- ?Oct 20, 2:20 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up 2.16% with 85 minutes remaining — a meaningful intraday move suggesting real institutional flow behind the move. No headline catalyst is identifiable, but absence of news does not disqualify continuation; large moves often precede or accompany fundamental shifts not yet reflected in public news. The macro backdrop (2-year yields running 2σ above trend at 4.74%) is modestly unfavorable for defensive/healthcare names in a risk-off rate environment, but GILD is a biotech/pharma with relatively low duration sensitivity compared to tech, so the rate headwind is muted. With 85 minutes remaining there is reasonable time for continuation into the close, though not enough to be highly confident in a sustained leg higher. No reversal pattern is evident from the data provided — the move appears clean from prior close. Given bounded downside (hard stop at -1.5%) and a +3% target, the asymmetry supports taking the position, though conviction is modest. Assigning slight above-neutral probability reflecting ordinary momentum with no strong fade signal.
- !Oct 20, 2:20 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is up 2.16% with 85 minutes remaining — a meaningful intraday move suggesting real institutional flow behind the move. No headline catalyst is identifiable, but absence of news does not disqualify continuation; large moves often precede or accompany fundamental shifts not yet reflected in public news. The macro backdrop (2-year yields running 2σ above trend at 4.74%) is modestly unfavorable for defensive/healthcare names in a risk-off rate environment, but GILD is a biotech/pharma with relatively low duration sensitivity compared to tech, so the rate headwind is muted. With 85 minutes remaining there is reasonable time for continuation into the close, though not enough to be highly confident in a sustained leg higher. No reversal pattern is evident from the data provided — the move appears clean from prior close. Given bounded downside (hard stop at -1.5%) and a +3% target, the asymmetry supports taking the position, though conviction is modest. Assigning slight above-neutral probability reflecting ordinary momentum with no strong fade signal.
- ?Oct 20, 10:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up 1.54% today with no attributed headline, suggesting this is likely flow-driven or sector-related buying rather than a single catalyst. The move is meaningful but below the 2-5% threshold that would indicate exceptional conviction. Macro context shows elevated 2Y rates (4.74, 2σ above trend), which is a headwind for rate-sensitive long-duration assets but GILD as a large-cap biotech/pharma is not the primary sector affected — Banks and Tech bear more of that pressure, so the macro read is roughly neutral for GILD. With 300 minutes remaining (full afternoon session ahead), there is ample time for continuation. No reversal signals or fade pattern described. No news means no catalyst to fade the move either. The setup is ordinary momentum — a modest intraday gain with no strong countervailing forces — warranting a slight lean toward continuation but not a high-conviction call. Probability sits just above the 0.5 threshold.
- !Oct 20, 10:45 AMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is up 1.54% today with no attributed headline, suggesting this is likely flow-driven or sector-related buying rather than a single catalyst. The move is meaningful but below the 2-5% threshold that would indicate exceptional conviction. Macro context shows elevated 2Y rates (4.74, 2σ above trend), which is a headwind for rate-sensitive long-duration assets but GILD as a large-cap biotech/pharma is not the primary sector affected — Banks and Tech bear more of that pressure, so the macro read is roughly neutral for GILD. With 300 minutes remaining (full afternoon session ahead), there is ample time for continuation. No reversal signals or fade pattern described. No news means no catalyst to fade the move either. The setup is ordinary momentum — a modest intraday gain with no strong countervailing forces — warranting a slight lean toward continuation but not a high-conviction call. Probability sits just above the 0.5 threshold.
- ?Oct 16, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $156.19 > MA150 $137.40 (+13.7%), MA rising, 2.7% off 52w high, vol 1.29× avg
- ?Oct 16, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $156.19 > MA150 $137.40 (+13.7%), MA rising, 2.7% off 52w high, vol 1.29× avg
- ?Oct 15, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $157.45 > MA150 $137.33 (+14.7%), MA rising, 1.9% off 52w high, vol 1.08× avg
- ?Oct 15, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $157.45 > MA150 $137.33 (+14.7%), MA rising, 1.9% off 52w high, vol 1.08× avg
- ?Oct 14, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $153.54 > MA150 $137.24 (+11.9%), MA rising, 2.4% off 52w high, vol 0.97× avg
- ?Oct 14, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $153.54 > MA150 $137.24 (+11.9%), MA rising, 2.4% off 52w high, vol 0.97× avg
- ?Oct 13, 1:00 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 1.67% today, which is a moderate but not outsized move. There are no recent headlines to explain the drop, suggesting this may be sector rotation or quiet institutional selling rather than a news-driven catalyst with follow-through momentum. The macro context shows the 10Y-3M spread at 0.99 (1.6σ above trend), which is mildly risk-positive and could support equity stability rather than further selling — though GILD as a defensive biotech name is not highly rate-sensitive. With 165 minutes remaining there is ample time for continuation, which is a positive factor for the trade. However, the absence of a clear catalyst, the moderate move magnitude (not yet at 2%+ conviction threshold), and a macro backdrop that doesn't strongly favor defensive sector selling all temper enthusiasm. No clear reversal signal is present either. Overall, this is a borderline read — the move has some momentum but lacks a compelling catalyst or macro tailwind to drive it materially lower into the close. Assigning minimum threshold probability given the bounded risk framework.
- !Oct 13, 1:00 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down 1.67% today, which is a moderate but not outsized move. There are no recent headlines to explain the drop, suggesting this may be sector rotation or quiet institutional selling rather than a news-driven catalyst with follow-through momentum. The macro context shows the 10Y-3M spread at 0.99 (1.6σ above trend), which is mildly risk-positive and could support equity stability rather than further selling — though GILD as a defensive biotech name is not highly rate-sensitive. With 165 minutes remaining there is ample time for continuation, which is a positive factor for the trade. However, the absence of a clear catalyst, the moderate move magnitude (not yet at 2%+ conviction threshold), and a macro backdrop that doesn't strongly favor defensive sector selling all temper enthusiasm. No clear reversal signal is present either. Overall, this is a borderline read — the move has some momentum but lacks a compelling catalyst or macro tailwind to drive it materially lower into the close. Assigning minimum threshold probability given the bounded risk framework.
- ?Oct 7, 12:01 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up 2.94% intraday with no attributable headline, suggesting real institutional flow drove the move rather than a news spike that might fade. The absence of a catalyst is not disqualifying — large uninformed observers often attribute moves to flow rebalancing, sector rotation, or pre-announcement accumulation. With 225 minutes remaining (roughly 3.75 hours), there is meaningful time for continuation into the close. The macro backdrop is modestly negative for rate-sensitive sectors given the elevated 5Y5Y forward inflation rate (2.35, 1.8σ above trend), but GILD as a large-cap biotech is not primarily rate-sensitive in the near term; this macro signal is a mild headwind at most. The main uncertainty is the lack of any confirming news or volume data — without knowing whether volume is running above average or whether this is a thin-market drift, confidence in sustained momentum is limited. On balance, the magnitude of the move is the strongest signal available and tilts toward continuation, but no strong accelerating factors are present to push confidence above 0.60. Assigning a modest continuation probability that clears the trade threshold.
- !Oct 7, 12:01 PMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
GILD is up 2.94% intraday with no attributable headline, suggesting real institutional flow drove the move rather than a news spike that might fade. The absence of a catalyst is not disqualifying — large uninformed observers often attribute moves to flow rebalancing, sector rotation, or pre-announcement accumulation. With 225 minutes remaining (roughly 3.75 hours), there is meaningful time for continuation into the close. The macro backdrop is modestly negative for rate-sensitive sectors given the elevated 5Y5Y forward inflation rate (2.35, 1.8σ above trend), but GILD as a large-cap biotech is not primarily rate-sensitive in the near term; this macro signal is a mild headwind at most. The main uncertainty is the lack of any confirming news or volume data — without knowing whether volume is running above average or whether this is a thin-market drift, confidence in sustained momentum is limited. On balance, the magnitude of the move is the strongest signal available and tilts toward continuation, but no strong accelerating factors are present to push confidence above 0.60. Assigning a modest continuation probability that clears the trade threshold.
- ?Oct 7, 9:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up 2.76% today with no attributable headline, suggesting this is either a technical breakout or institutional accumulation. The move is meaningful in magnitude — real flow drove this. However, several factors temper conviction: (1) No news catalyst identified, making it harder to assess whether the driver is sustained or a one-off order. (2) The macro context shows the 5Y5Y forward inflation rate elevated at 1.8σ above trend, which pressures rate-sensitive and high-multiple biotech/pharma names broadly — a mild headwind for continuation. (3) With 350 minutes remaining (roughly 5h50m), there is ample time for both continuation and reversal, so time is not a constraint either way. (4) Absence of a reversal pattern or fade signal means the base case leans toward momentum persistence. On balance, the move has enough residual momentum to warrant a modest continuation bias, but without a clear catalyst or sector tailwind to amplify conviction, this sits in the ordinary-momentum range.
- !Oct 7, 9:55 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
GILD is up 2.76% today with no attributable headline, suggesting this is either a technical breakout or institutional accumulation. The move is meaningful in magnitude — real flow drove this. However, several factors temper conviction: (1) No news catalyst identified, making it harder to assess whether the driver is sustained or a one-off order. (2) The macro context shows the 5Y5Y forward inflation rate elevated at 1.8σ above trend, which pressures rate-sensitive and high-multiple biotech/pharma names broadly — a mild headwind for continuation. (3) With 350 minutes remaining (roughly 5h50m), there is ample time for both continuation and reversal, so time is not a constraint either way. (4) Absence of a reversal pattern or fade signal means the base case leans toward momentum persistence. On balance, the move has enough residual momentum to warrant a modest continuation bias, but without a clear catalyst or sector tailwind to amplify conviction, this sits in the ordinary-momentum range.
- ?Sep 29, 12:25 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 1.58% today, which is a moderate but not outsized intraday move. No headlines are driving the move, which leaves it ambiguous — could be sector rotation, light profit-taking, or quiet selling. The macro context shows the 5-year forward inflation rate (T5YIFR) running 1.9σ above trend, which is mildly negative for rate-sensitive and growth-oriented large-cap biopharma like GILD, as higher inflation expectations can compress multiples and weigh on defensives. However, GILD is more of a value/dividend-oriented biotech name and not acutely rate-sensitive in the same way as utilities or REITs. With 200 minutes remaining (roughly 3.5 hours), there is ample time for continuation, but without a clear catalyst or evidence of sustained heavy selling pressure, the move looks more like drift than conviction momentum. The absence of news makes it harder to assign strong continuation odds. The -1.58% move is real but below the 2% threshold where momentum typically becomes self-reinforcing. Balancing time remaining (positive for continuation) against the lack of a clear driver and mild macro headwind that is only loosely applicable, I arrive just below 0.5 — not a strong enough setup to lean into the downside continuation.
- !Sep 29, 12:25 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down 1.58% today, which is a moderate but not outsized intraday move. No headlines are driving the move, which leaves it ambiguous — could be sector rotation, light profit-taking, or quiet selling. The macro context shows the 5-year forward inflation rate (T5YIFR) running 1.9σ above trend, which is mildly negative for rate-sensitive and growth-oriented large-cap biopharma like GILD, as higher inflation expectations can compress multiples and weigh on defensives. However, GILD is more of a value/dividend-oriented biotech name and not acutely rate-sensitive in the same way as utilities or REITs. With 200 minutes remaining (roughly 3.5 hours), there is ample time for continuation, but without a clear catalyst or evidence of sustained heavy selling pressure, the move looks more like drift than conviction momentum. The absence of news makes it harder to assign strong continuation odds. The -1.58% move is real but below the 2% threshold where momentum typically becomes self-reinforcing. Balancing time remaining (positive for continuation) against the lack of a clear driver and mild macro headwind that is only loosely applicable, I arrive just below 0.5 — not a strong enough setup to lean into the downside continuation.
- ?Sep 29, 10:55 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 1.70% today with no attributable headline catalyst, suggesting this is flow-driven or sympathy with broader market pressure. The macro context shows 5-year forward inflation expectations (T5YIFR) elevated at 1.9σ above trend — this is modestly negative for rate-sensitive equities broadly, and while biotech/pharma (GILD) is not the most rate-sensitive sector, elevated inflation expectations can weigh on growth-premium names. The move is meaningful but not extreme (below the 2-5% high-conviction threshold), and absence of news makes it harder to assess whether a specific catalyst is still working. With 290 minutes remaining (~4.8 hours, essentially the full afternoon session), there is ample time for continuation if selling pressure persists. However, a ~1.7% move without news can fade as opportunistic buyers step in at support, and there is no strong directional confirmation from sector-specific catalysts. Balancing the modest macro headwind, neutral-to-mild momentum signal, and sufficient time remaining, this reads as a borderline continuation setup — assigning 0.50 reflecting genuine uncertainty with a slight lean toward continued weakness given the macro backdrop.
- !Sep 29, 10:55 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down 1.70% today with no attributable headline catalyst, suggesting this is flow-driven or sympathy with broader market pressure. The macro context shows 5-year forward inflation expectations (T5YIFR) elevated at 1.9σ above trend — this is modestly negative for rate-sensitive equities broadly, and while biotech/pharma (GILD) is not the most rate-sensitive sector, elevated inflation expectations can weigh on growth-premium names. The move is meaningful but not extreme (below the 2-5% high-conviction threshold), and absence of news makes it harder to assess whether a specific catalyst is still working. With 290 minutes remaining (~4.8 hours, essentially the full afternoon session), there is ample time for continuation if selling pressure persists. However, a ~1.7% move without news can fade as opportunistic buyers step in at support, and there is no strong directional confirmation from sector-specific catalysts. Balancing the modest macro headwind, neutral-to-mild momentum signal, and sufficient time remaining, this reads as a borderline continuation setup — assigning 0.50 reflecting genuine uncertainty with a slight lean toward continued weakness given the macro backdrop.
- ?Sep 18, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $150.11 > MA150 $137.20 (+9.4%), MA rising, 4.6% off 52w high, vol 3.03× avg
- ?Sep 18, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $150.11 > MA150 $137.20 (+9.4%), MA rising, 4.6% off 52w high, vol 3.03× avg
- ?Sep 17, 6:00 PMdecisionconsidered
Agent 2 — Adaptive — considered
Stage 2: close $150.89 > MA150 $137.21 (+10.0%), MA rising, 4.1% off 52w high, vol 1.27× avg
- ?Sep 17, 6:00 PMdecisionconsidered
Agent 1 — Immutable — considered
Stage 2: close $150.89 > MA150 $137.21 (+10.0%), MA rising, 4.1% off 52w high, vol 1.27× avg
- ?Sep 8, 12:26 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 3.15% intraday with no attributable headline, suggesting institutional-driven selling or sector rotation rather than a news-driven spike that might quickly reverse. The move has real size and conviction behind it. The macro backdrop shows 5Y forward inflation expectations elevated at 1.7σ above trend — this is a mild headwind for rate-sensitive sectors broadly, though GILD as a biotech/pharma name is not the most rate-sensitive. With 200 minutes remaining there is meaningful time for the move to extend, though GILD is not in the most reactive sector to the macro signal. No reversal pattern is evident from the available data, and absence of news does not suggest a snap-back catalyst is imminent. The combination of a meaningful downside move, no reversal trigger, and adequate time remaining supports a modest continuation probability, though the lack of sector-specific macro pressure and absence of confirming headline context keeps conviction moderate rather than high.
- !Sep 8, 12:26 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
GILD is down 3.15% intraday with no attributable headline, suggesting institutional-driven selling or sector rotation rather than a news-driven spike that might quickly reverse. The move has real size and conviction behind it. The macro backdrop shows 5Y forward inflation expectations elevated at 1.7σ above trend — this is a mild headwind for rate-sensitive sectors broadly, though GILD as a biotech/pharma name is not the most rate-sensitive. With 200 minutes remaining there is meaningful time for the move to extend, though GILD is not in the most reactive sector to the macro signal. No reversal pattern is evident from the available data, and absence of news does not suggest a snap-back catalyst is imminent. The combination of a meaningful downside move, no reversal trigger, and adequate time remaining supports a modest continuation probability, though the lack of sector-specific macro pressure and absence of confirming headline context keeps conviction moderate rather than high.
- ?Sep 1, 3:35 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is up ~2% intraday with no attributable headline catalyst, suggesting the move may be driven by technical or flow-based factors rather than a sustained fundamental driver. With only 10 minutes remaining until the forced close at 3:45 PM ET, there is extremely limited time for further continuation — even a strong setup has almost no runway left. The macro context (elevated 2Y yields at 2σ above trend) is modestly unfavorable for risk assets broadly but GILD as a large-cap biotech/pharma is largely rate-insensitive in the short term. The absence of news is not disqualifying, but the combination of very little time remaining, no clear catalyst to sustain buying pressure, and the risk that end-of-day profit-taking fades the move into the close all argue against continuation. Probability set below 0.5 primarily due to the time constraint.
- !Sep 1, 3:35 PMsignalseverity 0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is up ~2% intraday with no attributable headline catalyst, suggesting the move may be driven by technical or flow-based factors rather than a sustained fundamental driver. With only 10 minutes remaining until the forced close at 3:45 PM ET, there is extremely limited time for further continuation — even a strong setup has almost no runway left. The macro context (elevated 2Y yields at 2σ above trend) is modestly unfavorable for risk assets broadly but GILD as a large-cap biotech/pharma is largely rate-insensitive in the short term. The absence of news is not disqualifying, but the combination of very little time remaining, no clear catalyst to sustain buying pressure, and the risk that end-of-day profit-taking fades the move into the close all argue against continuation. Probability set below 0.5 primarily due to the time constraint.
- ?Aug 28, 12:16 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 1.79% today with no attributable headlines, suggesting the move is either broad market-driven or idiosyncratic institutional flow. The macro context (elevated mortgage rates at 6.66%, 1.8σ above trend) is not directly relevant to GILD as a biotech/pharma name — no meaningful sector tailwind or headwind from that data. With 209 minutes remaining (roughly 3.5 hours), there is ample time for continuation, which is modestly supportive. However, the move is below the 2% threshold that typically signals strong conviction flow, and the absence of any news catalyst makes it harder to assign high continuation probability. No reversal signals are evident, and no thin-volume flags are raised. This is a borderline setup: the default lean per the framework is to take the trade given bounded risk, but the lack of catalyst, sub-2% move, and no sector corroboration keeps this at the minimum threshold rather than a high-conviction read.
- !Aug 28, 12:16 PMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down 1.79% today with no attributable headlines, suggesting the move is either broad market-driven or idiosyncratic institutional flow. The macro context (elevated mortgage rates at 6.66%, 1.8σ above trend) is not directly relevant to GILD as a biotech/pharma name — no meaningful sector tailwind or headwind from that data. With 209 minutes remaining (roughly 3.5 hours), there is ample time for continuation, which is modestly supportive. However, the move is below the 2% threshold that typically signals strong conviction flow, and the absence of any news catalyst makes it harder to assign high continuation probability. No reversal signals are evident, and no thin-volume flags are raised. This is a borderline setup: the default lean per the framework is to take the trade given bounded risk, but the lack of catalyst, sub-2% move, and no sector corroboration keeps this at the minimum threshold rather than a high-conviction read.
- ?Aug 28, 10:35 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 1.50% today with no attributable news catalyst, sitting near the lower bound of what constitutes a meaningful intraday move. The macro context (elevated mortgage rates) is not directly relevant to GILD as a large-cap biopharma, so no sector tailwind or headwind is present from that signal. With 310 minutes remaining (roughly 5 hours, meaning this is still early-to-mid session), there is ample time for the move to either continue or reverse. The move magnitude is modest rather than aggressive, which limits conviction on continuation — a 1.5% move in a stock like GILD could easily represent routine profit-taking or light selling rather than a strong directional flow with conviction. No reversal pattern is explicitly evident, but no strong continuation pressure signal exists either. Given the bounded risk profile of the system and the default lean toward taking borderline trades, this resolves at exactly 0.50 — a coin-flip lean toward continuation of the downward move, driven by existing momentum and adequate time remaining, but with no strong catalyst or sector confirmation to push conviction higher.
- !Aug 28, 10:35 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down 1.50% today with no attributable news catalyst, sitting near the lower bound of what constitutes a meaningful intraday move. The macro context (elevated mortgage rates) is not directly relevant to GILD as a large-cap biopharma, so no sector tailwind or headwind is present from that signal. With 310 minutes remaining (roughly 5 hours, meaning this is still early-to-mid session), there is ample time for the move to either continue or reverse. The move magnitude is modest rather than aggressive, which limits conviction on continuation — a 1.5% move in a stock like GILD could easily represent routine profit-taking or light selling rather than a strong directional flow with conviction. No reversal pattern is explicitly evident, but no strong continuation pressure signal exists either. Given the bounded risk profile of the system and the default lean toward taking borderline trades, this resolves at exactly 0.50 — a coin-flip lean toward continuation of the downward move, driven by existing momentum and adequate time remaining, but with no strong catalyst or sector confirmation to push conviction higher.
- ▣Aug 26, 8:00 PMjournaltarget
Agent 4 — Dip Buyer (Frozen) closed long 8 @ $148.09 (+$195.20)
Target hit: close $148.09 ≥ target $137.50
- ❖Aug 25, 9:35 AMnewsvia finnhub
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often
- ❖Aug 24, 2:15 PMnewsvia finnhub
$1000 Invested In Gilead Sciences 5 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.4% on an annualized basis producing an average annual return of 15.54%. Currently, Gilead Sciences has a market capitalization of
- ❖Aug 24, 9:35 AMnewsvia finnhub
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will
- ❖Aug 24, 2:33 AMnewsvia finnhub
Gilead’s Trodelvy-Keytruda Combo Gets EU Approval for Metastatic Breast Cancer
Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted marketing authorization for Trodelvy® (sacituzumab govitecan-hziy) in combination with Keytruda® (pembrolizumab) for the
- ❖Aug 10, 4:01 PMnewsvia finnhub
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
Completed acquisition of Ouro Medicines with Gilead Sciences to advance potential first and best-in-class T-cell engager Forecast at least €1.6B of cash remaining after funding portfolio to first gamgertamig approval Maintain year-end 2026 cash and financial investments balance guidance of ~€2B, and now includes €50M share repurchase Mechelen, Belgium; August 10, 2026, 22.01 CET; regulated information – Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced its half-year 2026 fin
- ❖Aug 10, 5:16 AMnewsvia finnhub
Gilead Sciences: The Market May Be Underestimating Its Growth (Rating Upgrade)
Gileadâs 2026 outlook improves as R&D pipeline accelerates and Biktarvy & Livdelzi sales rise, lifting guidance.
- ❖Aug 10, 1:01 AMnewsvia finnhub
GILD- An Attractive Biotech Stock with Solid Base Revenue Growth
Gilead Sciences Inc. (GILD) just reported June quarter revenue up 10.2% from last year to $7.8 billion, ahead of estimates. Due to an $11.2 billion one-time write-off of acquired in-process R&D, they reported a $6.75 per share pro forma loss. But that was smaller than the negative $7.25 consensus expectation, notes Michael Murphy, editor of New World Investor.
- ❖Aug 8, 10:07 AMnewsvia finnhub
Key HIV stat over 70% leaves BofA siding with Gilead
Gilead Sciences (GILD) closed a strong second quarter, and Wall Street noticed. The drugmaker beat sales expectations across its biggest franchises, raised its full-year outlook, and gave analysts fresh reasons to stay bullish heading into the back half of 2026. Bank of America was one of them. The ...
- ❖Aug 7, 11:39 AMnewsvia finnhub
What Insmed Stock's Premium Is Actually Buying
Management has just raised the peak-sales estimate, and a large slice of it belongs to a drug still running Phase III trials.
- ❖Aug 7, 10:00 AMnewsvia finnhub
GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength
Gilead raises its 2026 base-business outlook as HIV and PrEP momentum strengthens, while Trodelvy growth and two potential launches shape the second half.
- ❖Aug 7, 6:51 AMnewsvia finnhub
Amgen: The Market Is Underestimating Its Next Growth Phase
Amgen stock update: Tezspire and Repatha sales are surging as 2026 revenue guidance rises. Click here to read more about AMGN.
- ❖Aug 6, 2:52 PMnewsvia finnhub
KYMR Q2 Earnings and Revenues Top Estimates on Gilead, Sanofi Payments
Kymera Therapeutics beat revenue estimates as milestone payments boost results and advances KT-621 development, with key trial data expected by year-end.
- ❖Aug 6, 7:31 AMnewsvia finnhub
Gilead Sciences: A Strong Quarter Hidden Behind Ugly Earnings
Gilead Sciences is upgraded to a cautious 'Buy' after Q2/26, supported by robust revenue growth and raised guidance. Read more on GILD stock here.
- ❖Aug 6, 7:04 AMnewsvia finnhub
MSD and Gilead scrap Phase III Trodelvy-Keytruda study on lacklustre interim data
This study miss marks a setback for Gilead’s Trodelvy expansion plans, which include both mono and combination therapy approaches.
- ❖Aug 5, 11:41 PMnewsvia finnhub
Kathy Hochul Slams Trump Over Medicare Cut, Says 1.3 Million New Yorkers Will Pay More for Prescriptions: 'A New Assault on Seniors...'
Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 million New Yorkers.
- ❖Aug 5, 3:01 PMnewsvia finnhub
Compass Pathways PLC (CMPS) (Q2 2026) Earnings Call Highlights: Strong Cash Position and NDA ...
Compass Pathways PLC (CMPS) reports $433 million in cash and advances rolling NDA submission for COMP360 in treatment-resistant depression, targeting a first-half 2027 launch.
- ❖Aug 5, 1:04 PMnewsvia finnhub
Kymera Therapeutics Q2 Earnings Call Highlights
Kymera Therapeutics (NASDAQ:KYMR) said it completed enrollment in its Phase 2b atopic dermatitis trial of KT-621 about six months ahead of schedule, positioning the company to report top-line data by the end of 2026 and potentially begin Phase 3 development around mid-2027. Chief Executive Officer
- ❖Aug 5, 12:26 PMnewsvia finnhub
Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat
Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock slipped, still in a downtrend.
- ❖Aug 5, 12:12 PMnewsvia finnhub
Gilead (GILD) Faces HIV Drug Access Criticism From AIDS Healthcare Foundation
AIDS Healthcare Foundation publicly criticizes Gilead Sciences on its global HIV drug pricing and access policies. The advocacy group alleges that Gilead benefits from taxpayer-funded research while limiting affordable treatment options in low and middle income countries. The dispute focuses on licensing terms and pricing of key HIV therapies that are widely used in global treatment programs. Gilead Sciences (NasdaqGS:GILD) is a major player in HIV therapeutics, with its treatments used...
- ❖Aug 5, 11:22 AMnewsvia finnhub
GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised
GILD beats Q2 revenue estimates as HIV sales fuel growth, while acquisition charges cause a loss. Higher HIV guidance and pipeline progress support momentum.
- ?Aug 5, 10:56 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down ~3% today, a meaningful move with real seller conviction. The Q2 2026 earnings call headline (PrEP sales doubling to $1B, HIV growth) might initially seem positive, but the mid-session article explicitly frames the bull case as potentially weakening amid '2026 losses' — suggesting the market is digesting the earnings report negatively despite some strong metrics, possibly due to valuation concerns, guidance, or oncology segment underperformance not fully priced in. The macro backdrop (5Y inflation expectations 1.9σ below trend) is modestly risk-off and does not provide a tailwind for large-cap biotech. With 290 minutes remaining (roughly 4.8 hours), there is ample time for continuation if sellers maintain pressure. No clear reversal signal is present — absence of a sharp intraday bounce off lows, and the negative framing of the mid-session article suggests narrative is still bearish. The tight stop (-1.5%) and bounded risk profile support taking the trade at this modest probability. No strong catalyst for reversal is visible, so continuation is slightly favored, but uncertainty around post-earnings digest and potential buy-the-dip flows caps confidence.
- !Aug 5, 10:56 AMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
GILD is down ~3% today, a meaningful move with real seller conviction. The Q2 2026 earnings call headline (PrEP sales doubling to $1B, HIV growth) might initially seem positive, but the mid-session article explicitly frames the bull case as potentially weakening amid '2026 losses' — suggesting the market is digesting the earnings report negatively despite some strong metrics, possibly due to valuation concerns, guidance, or oncology segment underperformance not fully priced in. The macro backdrop (5Y inflation expectations 1.9σ below trend) is modestly risk-off and does not provide a tailwind for large-cap biotech. With 290 minutes remaining (roughly 4.8 hours), there is ample time for continuation if sellers maintain pressure. No clear reversal signal is present — absence of a sharp intraday bounce off lows, and the negative framing of the mid-session article suggests narrative is still bearish. The tight stop (-1.5%) and bounded risk profile support taking the trade at this modest probability. No strong catalyst for reversal is visible, so continuation is slightly favored, but uncertainty around post-earnings digest and potential buy-the-dip flows caps confidence.
- ❖Aug 5, 8:16 AMnewsvia finnhub
RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target from $120 to $123.
- ❖Aug 5, 8:14 AMnewsvia finnhub
The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth
In early August 2026, Gilead Sciences reported second-quarter revenue of US$7.80 billion but moved to a quarterly net loss of US$10.50 billion, widened its full-year 2026 loss guidance, and still affirmed a US$0.82 per-share dividend while continuing selective share repurchases. Despite the reported loss and higher projected operating loss for 2026, Gilead’s base business delivered its strongest second-quarter growth in three years, fueled by HIV and oncology therapies such as Yeztugo and...
- ❖Aug 5, 7:00 AMnewsvia finnhub
Earnings roundup: Gilead’s ‘uncertain’ future, Pfizer’s crossroads and Merck’s PCSK9 launch
Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change Pfizer’s growth trajectory.
- ❖Aug 5, 4:52 AMnewsvia finnhub
Cantor Fitzgerald Reiterates Overweight on Gilead Sciences, Maintains $155 Price Target
Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight and maintains $155 price target.
- ❖Aug 5, 2:02 AMnewsvia finnhub
Needham Reiterates Buy on Gilead Sciences, Maintains $170 Price Target
Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains $170 price target.
- ❖Aug 5, 1:06 AMnewsvia finnhub
Gilead Sciences Inc (GILD) (Q2 2026) Earnings Call Highlights: PrEP Sales Double to $1B, HIV ...
Gilead delivers strongest Q2 base business growth in 3 years, raises full-year HIV guidance, and showcases rapid uptake of Yeztugo and Trodelvy despite acquisition-related EPS drag.
- ❖Aug 4, 8:37 PMnewsvia finnhub
Gilead Sciences (NASDAQ:GILD) Posts Q2 Beat but Stock Slips on Full-Year Guidance
Gilead Q2 beats estimates but stock slips as full-year guidance disappoints, with heavy acquisition charges offsetting strong HIV and Trodelvy sales.
- ❖Aug 4, 8:04 PMnewsvia finnhub
Gilead Sciences Q2 Earnings Call Highlights
Gilead Sciences (NASDAQ:GILD) reported second-quarter 2026 base business sales growth of 10% year over year to $7.6 billion, supported by HIV treatments and prevention products, Trodelvy in oncology and Livdelzi in liver disease. The company raised its full-year base business sales outlook and incre
- ❖Aug 4, 7:00 PMnewsvia finnhub
Compared to Estimates, Gilead (GILD) Q2 Earnings: A Look at Key Metrics
The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- ❖Aug 4, 6:07 PMnewsvia finnhub
Gilead's High-Profile HIV Drug Beat, But That's Not What Grabbed Attention
Gilead Sciences narrowly beat sales expectations for its HIV PrEP drug, Yeztugo. Gilead stock edged lower late, still in a downtrend.
- ❖Aug 4, 5:20 PMnewsvia finnhub
Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call Transcript
Gilead Sciences, Inc. (GILD) Q2 2026 Earnings Call August 4, 2026 4:30 PM EDTCompany ParticipantsJacquie Ross - Senior Vice President of Treasury &...
- ❖Aug 4, 5:15 PMnewsvia finnhub
Gilead Sciences (GILD) Reports Q2 Loss, Beats Revenue Estimates
Gilead (GILD) delivered earnings and revenue surprises of +4.53% and +5.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- ❖Aug 4, 5:07 PMnewsvia finnhub
AHF Crowns Gilead Corporate Welfare King
LOS ANGELES, August 04, 2026--AHF Crowns Gilead Corporate Welfare King
- ❖Aug 4, 5:05 PMnewsvia finnhub
Gilead Sciences (NASDAQ:GILD) Beats Expectations in Strong Q2 CY2026
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 10.2% year on year to $7.80 billion. On the other hand, the company’s full-year revenue guidance of $30.25 billion at the midpoint came in 0.6% below analysts’ estimates. Its non-GAAP loss of $6.75 per share was 6.9% above analysts’ consensus estimates.
- ❖Aug 4, 4:12 PMnewsvia finnhub
Gilead Posts a Loss on Acquisitions but Revenue Tells a Bigger Story
Gilead Sciences posts higher revenue as its market-leading HIV drug portfolio continues to drive growth.
- ❖Aug 4, 4:07 PMnewsvia finnhub
Why Gilead's High-Profile HIV Drug Might Have To Play Catch-Up
Gilead Sciences narrowly beat sales expectations for HIV PrEP drug Yeztugo. But Gilead stock remains trapped below two key lines.
- ❖Aug 4, 4:01 PMnewsvia finnhub
Gilead Sciences Announces Second Quarter 2026 Financial Results
FOSTER CITY, Calif., August 04, 2026--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter 2026.
- ❖Aug 4, 2:10 PMnewsvia finnhub
Equities Rally Intraday Amid Upbeat Earnings, Hormuz Reopening Hopes
US equities rallied intraday, fueled by upbeat earnings reports and hopes that the Strait of Hormuz
- ❖Aug 4, 1:52 PMnewsvia finnhub
Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says
Merck's (MRK) "HIV pipeline" is brewing in the background, as weekly treatment are interesting and s
- ❖Aug 4, 1:17 PMnewsvia finnhub
Gilead Sciences Exec Says Raising Full Year HIV Growth Expectations To 9%-10% YoY From Prior Guidance Of 8% Growth; Launch Preparations Fully Underway For Anito-Cel Cell Therapy, With Five Months To Go Until FDA PDUFA Date; Do Not Currently Anticipate Pursuing Additional Sizable M&A Transactions This Year
-Conference Call
- ❖Aug 4, 1:06 PMnewsvia finnhub
Gilead Sciences, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-04. The following slide deck was published by Gilead Sciences, Inc.
- ❖Aug 4, 12:03 PMnewsvia finnhub
Gilead Sciences Lowers FY2026 GAAP EPS Guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) Est
Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40) vs $(2.77) analyst estimate..
- ❖Aug 4, 12:02 PMnewsvia finnhub
Gilead Sciences Raises FY2026 Adj EPS Guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) Est; Raises FY2026 Sales Guidance from $30.000B-$30.400B to $30.100B-$30.400B vs $30.427B Est
Gilead Sciences (NASDAQ:GILD) raises FY2026 Adj EPS guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30) vs $(0.75) analyst estimate. Raises FY2026 sales outlook from $30.000 billion-$30.400 billion to $30.100
- ❖Aug 4, 12:01 PMnewsvia finnhub
Gilead Sciences Q2 Adj. EPS $(6.75) Beats $(7.24) Estimate, Sales $7.803B Beat $7.400B Estimate
Gilead Sciences (NASDAQ:GILD) reported quarterly losses of $(6.75) per share which beat the analyst consensus estimate of $(7.24) by 6.64 percent. This is a 435.82 percent decrease over earnings of $2.01 per share from
- ❖Aug 4, 11:19 AMnewsvia finnhub
Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo?
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
- ❖Aug 4, 8:30 AMnewsvia finnhub
Compugen Ltd. Q2 2026 Earnings Call Summary
Moby summary of Compugen Ltd.'s Q2 2026 earnings call
- ❖Aug 4, 8:30 AMnewsvia finnhub
Gilead Sciences, Inc. Q2 2026 Earnings Call Summary
Moby summary of Gilead Sciences, Inc.'s Q2 2026 earnings call
- ❖Aug 4, 8:00 AMnewsvia finnhub
Rani Therapeutics Appoints Michelle Gilson to Board of Directors
~ Former Chief Financial Officer of Arcellx Brings Deep Capital Markets and Biotech Financial Leadership Experience ~SAN JOSE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced the appointment of Michelle Gilson to its Board of Directors. Ms. Gilson will serve as Chair of the Audit Committee. "The combination of deep capital markets expertise and hands-on finan
- ❖Aug 4, 7:58 AMnewsvia finnhub
Stocks Rise Pre-Bell Ahead of Latest Round of Earnings; Investors Gauge Uncertainty Over Potential US-Iran Deal
US equity futures were tracking in the green on Tuesday as traders await the latest batch of corpora
- ❖Aug 3, 2:01 PMnewsvia finnhub
Merck Spotlights Weekly HIV Treatment, Monthly PrEP as $5B Growth Opportunity
Merck & Co., Inc. (NYSE:MRK) outlined its HIV treatment and prevention strategy at an investor event following the International AIDS Conference, highlighting Phase III results for a once-weekly oral HIV regimen and its plans for a monthly oral pre-exposure prophylaxis, or PrEP, candidate. Comp
- ?Jul 30, 10:01 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 2.17% with 345 minutes (nearly a full session) remaining, so there is ample time for the move to continue or reverse. The headlines are mildly bullish/neutral in tone (value arguments, Trodelvy progress, 'buy the distortion' framing ahead of Q2), which could act as a soft counterweight to downside momentum but are pre-market opinion pieces rather than hard catalysts driving the move. The macro backdrop shows 5-year inflation expectations 1.5σ below trend, which is modestly risk-supportive and favors sectors like gold/energy over biotech/pharma — not a direct headwind for GILD but not a tailwind either. The absence of a clear negative catalyst for the decline is mildly suspicious (could be broad sector rotation or quiet distribution), but the 2.17% move itself represents real selling conviction. With no strong reversal signal, no obvious buy-the-news catalyst imminent, and the headlines framing GILD as a value play that may need Q2 earnings to 'clear up distortion,' there is modest reason to expect sellers remain in control into the close. Probability is only marginally above 0.5 given the muted macro support and constructive analyst tone that could attract dip buyers throughout the session.
- !Jul 30, 10:01 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down 2.17% with 345 minutes (nearly a full session) remaining, so there is ample time for the move to continue or reverse. The headlines are mildly bullish/neutral in tone (value arguments, Trodelvy progress, 'buy the distortion' framing ahead of Q2), which could act as a soft counterweight to downside momentum but are pre-market opinion pieces rather than hard catalysts driving the move. The macro backdrop shows 5-year inflation expectations 1.5σ below trend, which is modestly risk-supportive and favors sectors like gold/energy over biotech/pharma — not a direct headwind for GILD but not a tailwind either. The absence of a clear negative catalyst for the decline is mildly suspicious (could be broad sector rotation or quiet distribution), but the 2.17% move itself represents real selling conviction. With no strong reversal signal, no obvious buy-the-news catalyst imminent, and the headlines framing GILD as a value play that may need Q2 earnings to 'clear up distortion,' there is modest reason to expect sellers remain in control into the close. Probability is only marginally above 0.5 given the muted macro support and constructive analyst tone that could attract dip buyers throughout the session.
- ✓Jul 27, 10:46 AMdecisionacted
Agent 7 — Day Trader — decide: buy
GILD is up 2.75% today, a meaningful move indicating real institutional flow. With 300 minutes remaining (a full session effectively), there is ample time for continuation into the close. No specific catalyst headline is present for GILD itself, but absence of news does not negate the move — the price action itself is the signal. The macro context (5Y inflation expectations running 1.6σ below trend) is mildly favorable for large-cap healthcare/biotech as a defensive growth play, since lower inflation expectations support rate-sensitive and growth-oriented sectors. The biotech ETF comparison headline is sector-level noise, not a GILD-specific headwind. No reversal pattern is evident — the move appears directional rather than a fade. With 300 minutes left and a 2.75% gap already established, the risk is that the stock consolidates rather than extends, but the bounded risk framework (tight stop, fixed target) favors leaning into the momentum. Probability held at modest continuation levels rather than high conviction given no confirmed catalyst.
- ▢Jul 26, 8:00 PMjournal
Agent 7 — Day Trader opened long 21 @ $132.86
- ▣Jul 26, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 21 @ $131.05 (-$38.01)
EOD forced close — day trader never carries overnight
- ?Jul 21, 9:35 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down ~2.06% today with 370 minutes remaining (well into the session but still significant time to close). The move has size — someone with conviction sold — but the catalyst is ambiguous: the headline references an analyst research call on GILD but gives no detail on whether it was an upgrade or downgrade. A 2% decline on an analyst note is consistent with a downgrade or price target cut, which typically sees continuation as momentum traders and stop-losses layer in. The macro backdrop (T10Y2Y at 0.39, 1.5σ below trend, bear-flattening pressure) is mildly supportive of defensives like GILD under normal conditions, which could act as a mild headwind to further downside — but this effect is sector-level and not strong enough to override stock-specific flow. No clear reversal signal or fade pattern is evident from the data provided. With ample time remaining and a meaningful initial move, the base case leans toward modest continuation, but the uncertain catalyst and defensive sector tailwind prevent a high-conviction read. Probability set at 0.53 — slight lean toward continuation of the downtrend into the close.
- !Jul 21, 9:35 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down ~2.06% today with 370 minutes remaining (well into the session but still significant time to close). The move has size — someone with conviction sold — but the catalyst is ambiguous: the headline references an analyst research call on GILD but gives no detail on whether it was an upgrade or downgrade. A 2% decline on an analyst note is consistent with a downgrade or price target cut, which typically sees continuation as momentum traders and stop-losses layer in. The macro backdrop (T10Y2Y at 0.39, 1.5σ below trend, bear-flattening pressure) is mildly supportive of defensives like GILD under normal conditions, which could act as a mild headwind to further downside — but this effect is sector-level and not strong enough to override stock-specific flow. No clear reversal signal or fade pattern is evident from the data provided. With ample time remaining and a meaningful initial move, the base case leans toward modest continuation, but the uncertain catalyst and defensive sector tailwind prevent a high-conviction read. Probability set at 0.53 — slight lean toward continuation of the downtrend into the close.
- ?Jul 10, 12:12 PMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down 3.30% intraday with no attributable headline, suggesting either sector rotation, institutional distribution, or a large block trade driving the move. The absence of news is not disqualifying — significant flow has clearly entered on the sell side. Macro context shows 10Y inflation expectations (T10YIE) running 1.5σ below trend, which favors long-duration assets but is mildly negative for pharma/biotech names that carry high valuation multiples, as lower inflation expectations can coincide with risk-off or growth concern sentiment. With 214 minutes remaining there is ample time for continuation — this is not a late-day setup where time decay would argue against the trade. However, a 3.3% move without a catalyst introduces mean-reversion risk; if this was a single large seller the float may have absorbed the print and stabilization could follow. No reversal pattern is evident from the data provided. On balance, momentum is the dominant factor here — the move is real, time is sufficient, and macro context does not actively oppose downside. Probability is modest rather than high because no catalyst is present to sustain institutional conviction into the close, and the move is already at the upper boundary of a typical single-session swing. Slight lean toward continuation.
- !Jul 10, 12:12 PMsignalseverity -0.03
Agent 7 — Day Trader — day_trade_skipped
GILD is down 3.30% intraday with no attributable headline, suggesting either sector rotation, institutional distribution, or a large block trade driving the move. The absence of news is not disqualifying — significant flow has clearly entered on the sell side. Macro context shows 10Y inflation expectations (T10YIE) running 1.5σ below trend, which favors long-duration assets but is mildly negative for pharma/biotech names that carry high valuation multiples, as lower inflation expectations can coincide with risk-off or growth concern sentiment. With 214 minutes remaining there is ample time for continuation — this is not a late-day setup where time decay would argue against the trade. However, a 3.3% move without a catalyst introduces mean-reversion risk; if this was a single large seller the float may have absorbed the print and stabilization could follow. No reversal pattern is evident from the data provided. On balance, momentum is the dominant factor here — the move is real, time is sufficient, and macro context does not actively oppose downside. Probability is modest rather than high because no catalyst is present to sustain institutional conviction into the close, and the move is already at the upper boundary of a typical single-session swing. Slight lean toward continuation.
- ?Jul 10, 10:25 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
GILD is down ~2% intraday with no attributable headline, suggesting the move is driven by technical selling or quiet institutional flow rather than a catalyst. With 320 minutes (over 5 hours) remaining until the forced close, there is ample time for the move to extend. However, several factors temper conviction: (1) no news catalyst means the move could exhaust and reverse without a sustained narrative; (2) the macro backdrop shows T10YIE at 1.5σ below trend, indicating compressed inflation expectations and lower rates — this environment is generally supportive of defensive/pharma names like GILD rather than bearish, suggesting some headwind to further downside; (3) the ~2% move sits at the lower bound of 'meaningful' momentum, not deeply oversold intraday. Absent a clear reversal signal and with time on side, the baseline continuation probability edges just above 0.5, but the rate environment provides mild resistance to further selling. Taking a modest lean toward continuation at 0.52.
- !Jul 10, 10:25 AMsignalseverity -0.02
Agent 7 — Day Trader — day_trade_skipped
GILD is down ~2% intraday with no attributable headline, suggesting the move is driven by technical selling or quiet institutional flow rather than a catalyst. With 320 minutes (over 5 hours) remaining until the forced close, there is ample time for the move to extend. However, several factors temper conviction: (1) no news catalyst means the move could exhaust and reverse without a sustained narrative; (2) the macro backdrop shows T10YIE at 1.5σ below trend, indicating compressed inflation expectations and lower rates — this environment is generally supportive of defensive/pharma names like GILD rather than bearish, suggesting some headwind to further downside; (3) the ~2% move sits at the lower bound of 'meaningful' momentum, not deeply oversold intraday. Absent a clear reversal signal and with time on side, the baseline continuation probability edges just above 0.5, but the rate environment provides mild resistance to further selling. Taking a modest lean toward continuation at 0.52.
- !Jul 2, 6:03 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 5:45 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 5:31 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 5:16 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 5:04 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 4:46 PMsignal
options_momentum — insufficient_capital
- !Jul 2, 4:33 PMsignal
options_momentum — insufficient_capital
- ?Jun 29, 10:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
Several factors argue against continuation of the downside move. Most importantly, a recent headline from today (12:22 UTC) notes GILD moved 3.3% HIGHER, suggesting the stock may have already seen a sharp intraday reversal pattern — a pop followed by a fade back down to -1.67% is a classic reversal/fade structure, not a clean trending move. This kind of whipsaw behavior suggests the downside momentum is not clean or conviction-driven. Additionally, macro context shows T10YIE at 2.1σ below its 24-month trend, meaning inflation expectations are suppressed — this is supportive for long-duration assets and biotech/pharma names like GILD, providing a modest macro tailwind against further downside. The dividend-focused headline also reinforces a value/income bid that could support the stock into the close. With 300 minutes remaining there is ample time, but the reversal pattern off intraday highs back through flat and into negative territory raises concern about choppy, directionless price action rather than a clean trend to fade into the close. The -1.67% move is meaningful but the context suggests it is a give-back of an earlier spike rather than fresh initiated selling. Probability of downside continuation falls below the 0.5 threshold; no position is triggered.
- ✓Jun 26, 10:11 AMdecisionacted
Agent 7 — Day Trader — decide: buy
GILD is up 2.71% on a concrete catalyst — Cantor Fitzgerald reiterating Overweight following positive HIV trial results, which is a credible, specific, fundamental driver. Analyst reiterations post-trial data tend to attract incremental buy-side attention through the session as the note circulates. The prior day's dip headline suggests the stock was oversold into this catalyst, which adds to the setup. Macro context is mildly supportive: T10YIE at 1.9σ below trend implies lower real rates / inflation expectations, which is generally favorable for long-duration healthcare/biotech names. With 335 minutes remaining there is ample time for continuation. No reversal signals noted. The main drag on conviction is that the move is already 2.71%, limiting the remaining distance to the +3% profit target from current levels — but from the prior close that target sits around $127.55, which is only ~$0.35 away, making a quick fill plausible. No evidence of fade or volume thinning. Probability set at 0.63 reflecting solid but not exceptional continuation setup.
- ▢Jun 25, 8:00 PMjournal
Agent 7 — Day Trader opened long 23 @ $127.20
- ▣Jun 25, 8:00 PMjournaltime_stop
Agent 7 — Day Trader closed long 23 @ $125.57 (-$37.61)
EOD forced close — day trader never carries overnight
- ✓Jun 18, 6:21 PMdecisionacted
Agent 4 — Dip Buyer (Frozen) — decide: buy
Gilead Sciences is a large-cap, well-established biopharmaceutical company with durable cash flows from its HIV and oncology franchises, and no recent news or SEC filings in the window suggest any fundamental deterioration driving this 10% pullback. The macro context shows a compressed yield curve (T10Y2Y at 0.29, 3.5σ below trend), which is consistent with a risk-off or defensive rotation environment that could temporarily weigh on even high-quality healthcare names. Given the absence of company-specific negative catalysts, this drop appears to be macro/sector-rotation driven rather than a reflection of underlying business weakness.
- ?Jun 18, 6:05 PMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $63.15 cash available; close=$123.69.
- ▢Jun 17, 8:00 PMjournal
Agent 4 — Dip Buyer (Frozen) opened long 8 @ $123.69
- ▣Jun 10, 8:00 PMjournalstop
options_momentum closed long 200 @ $1.16 (-$202.76)
Stop: premium $1.16 ≤ trailing floor $1.81 (peak $2.42 × 0.75)
- ▣Jun 10, 8:00 PMjournalstop
options_momentum closed long 70 @ $1.29 (-$195.68)
Stop: premium $1.29 ≤ trailing floor $1.81 (peak $2.42 × 0.75)
- ▣Jun 9, 8:00 PMjournaltarget
options_momentum closed long 30 @ $8.39 (+$129.19)
De-risk: premium $8.39 ≥ 2.0× entry $4.08. Selling 30/100 contracts; trailing the remainder.
- ▢Jun 9, 8:00 PMjournal
options_momentum opened long 200 @ $2.18
- ▢Jun 3, 8:00 PMjournal
options_momentum opened long 30 @ $4.08
- ▢Jun 3, 8:00 PMjournal
options_momentum opened long 70 @ $4.08